Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.

Authors :: Brittenham GM
Nathan DG
Olivieri NF
Pippard MJ
Weatherall DJ
Source :: Lancet (London, England) [Lancet] 2003 Jan 11; Vol. 361 (9352), pp. 183; author reply 183-4.
Publication Year :: 2003

Subjects :: Cardiomyopathies mortality
Deferiprone
Humans
Reproducibility of Results
beta-Thalassemia mortality
Deferoxamine therapeutic use
Iron Chelating Agents therapeutic use
Pyridones therapeutic use
beta-Thalassemia drug therapy

Full Text Access

Tools